Comparison of mammosphere formation from stem-like cells of normal breast, malignant primary breast tumors, and MCF-7 cell line

Ambrose, Jenifer Mallavarpu; Veeraraghavan, Vishnu Priya; Vennila, Rosy; Rupert, Secunda; Sathyanesan, Jeswanth; Meenakshisundaram, Rajasundari; Selvaraj, Sakthivel; Malayaperumal, Sarubala; Kullappan, Malathi; Dorairaj, Sudarsanam; Gujarathi, Jayesh R; Gandhamaneni, Sri Harshini; Surapaneni, Krishna Mohan

doi:10.1186/s43046-022-00152-1

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MDA-MB-468 and MDA-MB-436 represents other TNBC cell lines frequently used to study stem-cell characteristics ( Li et al, 2018aLi et al, 2018a ). In addition, MCF-7 is a luminal subtype breast cancer cell line ( Ambrose et al, 2022 ) also frequently utilized to study stem-ness properties of breast cancer.…”

Section: Current Research On Flavonoids Targeting Cscs With the Poten...mentioning

confidence: 99%

Therapy-resistant breast cancer in focus: Clinically relevant mitigation by flavonoids targeting cancer stem cells

et al. 2023

View full text Add to dashboard Cite

Significant limitations of the reactive medical approach in breast cancer management are clearly reflected by alarming statistics recorded worldwide. According to the WHO updates, breast malignancies become the leading cancer type. Further, the portion of premenopausal breast cancer cases is permanently increasing and demonstrates particularly aggressive patterns and poor outcomes exemplified by young patients with triple-negative breast cancer that lacks targeted therapy. Accumulating studies suggest the crucial role of stem cells in tumour biology, high metastatic activity, and therapy resistance of aggressive breast cancer. Therefore, targeting breast cancer stem cells is a promising treatment approach in secondary and tertiary breast cancer care. To this end, naturally occurring substances demonstrate high potential to target cancer stem cells which, however, require in-depth analysis to identify effective anti-cancer agents for cost-effective breast cancer management. The current article highlights the properties of flavonoids particularly relevant for targeting breast cancer stem cells to mitigate therapy resistance. The proposed approach is conformed with the principles of 3P medicine by applying predictive diagnostics, patient stratification and treatments tailored to the individualised patient profile. Expected impacts are very high, namely, to overcome limitations of reactive medical services improving individual outcomes and the healthcare economy in breast cancer management. Relevant clinical applications are exemplified in the paper.

show abstract

Section: Current Research On Flavonoids Targeting Cscs With the Poten...mentioning

confidence: 99%

Therapy-resistant breast cancer in focus: Clinically relevant mitigation by flavonoids targeting cancer stem cells

et al. 2023

View full text Add to dashboard Cite

show abstract

“…In experiments using multiple CSC probe systems for metabolic fractionation via flow cytometry, a subpopulation of MCF7 cells displayed heightened PGC1α activity, elevated mitochondrial ROS/H 2 O 2 production, and increased NADH levels-distinctive features of the CSC metabolic phenotype that are indicative of higher mitochondrial biogenesis and metabolism [39]. Furthermore, in experiments using the mammosphere formation assay, a tool employed to assess the activity of putative breast CSCs in non-adherent in vitro cultures [181], these cells exhibited enhanced mammosphere formation capacity [39]. Intriguingly, VC was observed to induce oxidative stress and impede the activity of GAPDH, a pivotal glycolytic enzyme [39].…”

Section: Targeting Breast Cancer Stem Cells With Vitamin Cmentioning

confidence: 99%

Role of Vitamin C in Targeting Cancer Stem Cells and Cellular Plasticity

Lee

2023

Cancers

View full text Add to dashboard Cite

Vitamin C (VC) is an essential nutrient that is vital for maintaining cellular physiology. Interestingly, it functions as either an antioxidant or a pro-oxidant, depending on the concentration used. At high-doses, VC selectively targets various cancer cell types through its pro-oxidant action, while at low-doses, VC enhances anti-tumor immunity by acting as an antioxidant. This versatility makes VC a promising anti-tumor agent for both standalone and combination therapies. Tumors consist of diverse cancer cell subtypes with distinct phenotypic and functional characteristics. In particular, cancer stem cells (CSCs), which are self-renewing multi-potent cells, are responsible for tumor recurrence, metastasis, chemoresistance, and heightened mortality. CSCs are often associated with the epithelial–mesenchymal transition (EMT), which confers increased motility and invasive capabilities that are characteristic of malignant and drug-resistant cells. Thus, eradicating CSC populations is crucial and has led to extensive efforts aimed at identifying medicines that can target them. Recent studies suggest that VC can selectively target CSCs via epigenetic and metabolic pathways in various cancers. Here, we highlight recent progress that has been made in understanding how VC effectively targets CSC evolution, providing a rationale for the use of VC either alone or in combination with other treatments to improve outcomes.

show abstract

Heterogeneity of the Alpha-Smooth Muscle Actin Tumor Score in Breast Cancer Cells Significantly Affects Tumor Invasiveness, Recurrence, and Patient Survival

Pasca Fenesan,

Cosma,

Melnic

et al. 2024

Cureus

View full text Add to dashboard Cite

Background: Alpha-smooth muscle actin (αSMA) has been widely investigated in malignancies, primarily concerning its expression in cancer-associated fibroblasts (CAFs) inside the tumor stroma. Microscopic examination indicates that αSMA expression is not confined to the tumor stromal compartment but is also present in a subset of tumor cells, and this expression correlates with an enhanced invasive phenotype of malignant cells from lung, liver, or ovarian malignancies. Information on actin expression in breast cancer (BC) cells is scarce, and its influence on clinicopathological characteristics remains ambiguous due to conflicting findings in the literature. Objective: To examine the αSMA tumor score in breast cancer cells utilizing digital image analysis (DIA) methodologies and to critically analyze the varying effects of αSMA tumor score values on clinicopathologic parameters, particularly focusing on tumor cell invasiveness, recurrence, and survival. Materials and methods: Double immunostaining for CD34 and αSMA was conducted on 53 breast cancer cases that were thoroughly characterized in relation to clinicopathologic data. Double immunostaining for CD34 and αSMA demonstrated different distribution patterns of both markers in normal and breast cancer tissues. DIA data about αSMA tumor cell density, intensity, tumor score, and histological score were correlated with clinicopathological factors. Results: We delineated three unique breast cancer subgroups based on αSMA tumor scores: a 9.43% low-expressing subgroup (αSMA_TS low , score 4), a 35.07% medium-expressing subgroup (αSMA_TS med , scores 5 and 6), and a 55.5% high-expressing subgroup (αSMA_TS high , scores 7 and 8). Stromal immature vessels and tertiary lymphoid structures (TLS) exhibited a strong correlation with αSMA_TS low , whereas recurrence, perineural, and lymphovascular invasion strongly influenced the αSMA_TS med and αSMA_TS high subgroups. The αSMA_TS med subgroup demonstrated the most heterogeneity with the influence of αSMA-expressing breast cancer cells on tumor size, nodal status, perineural and lymphovascular invasion, menopausal status, recurrence, and survival. Most of the cases from the αSMA_TS low subgroup had Luminal B and Luminal B-HER2 phenotypes, while triple-negative breast cancer (TNBC) represented one-third of all cases in the αSMA_TS high subgroup. Conclusion: αSMA-expressing breast cancer cells variably affect malignant growth, invasion, and recurrence, highly contingent upon their density and expression intensity. The current investigation identified an αSMA_TS med BC subgroup that appears to promote invasiveness, recurrence, and survival in breast cancer. Our data indicate that αSMA BC-expressing cells play a dual role in BC progression, contingent upo...

show abstract

Comparison of mammosphere formation from stem-like cells of normal breast, malignant primary breast tumors, and MCF-7 cell line

Cited by 3 publications

References 24 publications

Therapy-resistant breast cancer in focus: Clinically relevant mitigation by flavonoids targeting cancer stem cells

Therapy-resistant breast cancer in focus: Clinically relevant mitigation by flavonoids targeting cancer stem cells

Role of Vitamin C in Targeting Cancer Stem Cells and Cellular Plasticity

Heterogeneity of the Alpha-Smooth Muscle Actin Tumor Score in Breast Cancer Cells Significantly Affects Tumor Invasiveness, Recurrence, and Patient Survival

Contact Info

Product

Resources

About